With 27 years of experience in conducting HIV research including HIV vaccine, HIV biomedical prevention
and treatment in various populations to develop academic knowledge on HIV / AIDS,
we have worked in collaboration with leading international research networks and other domestic agencies.
Our diverse research programs are up-to-date with present situation and necessity of knowledge both nationally and globally
We are ready to expand our field of expertise to other challenging infectious diseases and substance use
News and Activities
To find more information, click the image
Impact of the Covid Epidemic on Alcohol Consumption in Thai Society By Kaittha Thaikla and team
The fully renovated Family clinic has re-opened for the IMPAACT 2019 study and other maternal and child health research.
Community Relation Unit newsletter January - March 2021 has been issued. Click the image to read more
The article entitled "Online Drug Marketing" written by Kanittha Thaikla, head of Substance Unit, was published on ASEAN Drug Monitoring Report 2019
The US NIH announced its next seven-year HIV research grants to 35 CTUs worldwide. RIHES, in collaboration with the Thai Red Cross AIDS Research Center as the Thai CTU, has continued to receive the grant for the third round.
Research Studies Currently Underway
To learn more, click Study title (to visit webpage) or Study snapshot (in Thai)
Research Institute for Health Sciences, Chiang Mai University
110 Intavaroros Road, Sriphum, Muang
Chiang Mai 50200 THAILAND
Tel. 66 5393 6148
The purpose of this study is to evaluate response to and safety of the HBV vaccine HEPLISAV-B in two study populations living with HIV: prior HBV vaccine recipients who are deemed non-responders and individuals who are naïve to HBV vaccination.
Study vaccines: HEPLISAV-B vs. Engerix-B
Respiratory syncytial virus (RSV) is a common and very contagious virus that infects the respiratory tract of most children before their second birthday. At present, there is no specific treatment
JNJ-53718678 is a novel drug and is under development for the treatment of RSV infection. This study purpose is to evaluate safety and antiviral activity of JNJ-53718678 in Children aged 28 days to 3 years with RSV infection